MedTrace Logo

Decitabine, Cytarabine, GCSF for Refractory AML/MDS

NCT00740181 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2022-01-14

Study results available
· View outcomes & findings →

Summary

This study will determine the activity of decitabine, low dose cytarabine (ARA-C) and G-CSF for patients with myelodysplasia and leukemia.

Conditions

Interventions

DRUG

chemotherapy

Sponsors & Collaborators

  • Memorial Hospital of Rhode Island

    collaborator OTHER

  • Roger Williams Medical Center

    collaborator OTHER

  • Brown University

    lead OTHER

Principal Investigators

  • James Butera · Brown University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2010-02-28
Completion
2010-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00740181 on ClinicalTrials.gov